# OnCo record remestemcel-l (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/remestemcel-l/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "remestemcel-l" ;
  schema:name "Remestemcel-L"@en ;
  schema:description "Donor bone marrow stromal cells given to children whose acute graft-versus-host disease no longer responds to steroids, the first mesenchymal stromal cell therapy approved in the United States."@en ;
  schema:url <https://onco.cc/drugs/remestemcel-l/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.bbmt.2020.01.018>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4e0918f-7444-4694-adeb-d38d98345659>, <https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host> ;
  onco:status "approved" ;
  onco:modality "Allogeneic bone marrow-derived mesenchymal stromal cell therapy" ;
  schema:alternateName "Ryoncil" ;
  onco:approval "US 2024: Steroid-refractory acute graft-versus-host disease in children aged two months and older" ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/gvhd-ruxolitinib-steroid-refractory/> ;
  onco:companies <https://onco.cc/companies/mesoblast/> ;
  onco:terms <https://onco.cc/terms/gvhd/> ;
  onco:trials <https://onco.cc/trials/msb-gvhd001/> .